References
- Clarke BF, Campbell IW. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. Br Med J. 1977;2(6102):1576–1578.
- Campbell IW, Howlett HCS. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev. 1995;11(S1):S57–S62.
- Campbell IW. Metformin and glibenclamide: comparative risks. Br Med J. 1984;289(6440):289.
- Campbell IW. Metformin and the sulphonylureas: the comparative risk. Macrovasc Dis Diabetes. 1985;15:105–110.
- De Fronzo RA, Goodman AM. Multicenter metformin study group. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med. 1995;333(9):541–549.
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–855.
- Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
- Bailey CJ, Campbell IW, Chan JCN, et al., editors. Metformin – the gold standard: a scientific handbook. Chichester (UK): Wiley; 2007.
- Campbell IW, Howlett HCS, Holman RR, et al., editors. Metformin; 60 years of clinical experience for a better tomorrow. Weinheim (Germany): Wiley; 2017.
- Petrie JR, Rossing PR, Campbell IW. Metformin and cardiorenal outcomes in diabetes: a reappraisal. Diabetes Obes Metab. 2020;22(6):904–915.
- VA Impact trial [Internet]. [cited 2021 Oct 15]. Available from: https://clinicaltrials.gov. NCT02915198
- SMARTEST trial [Internet]. [cited 2021 Oct 15]. Available from: https://clinicaltrials.gov. NCT03982381
- RENOMET trial [Internet]. [cited 2021 Oct 15]. Available from: https://clinicaltrials.gov. NCT03831464
- Rowan JA, Hague WM, Gao W, et al. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008;358(19):2003–2015.
- CLUE – Consequences for life of children with in utero exposure to metformin in Finland – a register-based cohort study (CLUE) [Internet]. [cited 2021 Nov 9]. Available from: http://www.encepp.eu/encepp/viewResource.htm;jsessionid=lg_7FoIbsoh_78NCd-SR27l97oStDDTHmOq470Yw_iTO9cPhES9R!491505511?id=40074
- Campbell IW. Metformin use in gestational diabetes. In: Mhmmod T, Arulkamaram S, Chervenak F, editors. Obesity and reproductive health. 2nd ed. Amsterdam (The Netherlands): Elsevier; 2020. p. 173–178.
- Hostalek U, Campbell IW. Metformin for diabetes prevention: an update of the evidence base. Curr Med Res Opin. 2021;37(10):1705–1717.
- Gong J, Kelekar G, Shen J, et al. The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development. Target Oncol. 2016;11(4):447–467.
- MAP trial [Internet]. [cited 2021 Oct 16]. Available from: https://clinicaltrials.gov. NCT04098666
- Kulkarni AS, Gubbi S, Barzilai N, et al. Benefits of metformin in attenuating the hallmarks of aging. Cell Metab. 2020;32(1):15–30.
- Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566–1576. DOI